Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Robert Sebra
Icahn School of Medicine at Mount Sinai, Department: Psychiatry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sema4
Salary not from the awardee Institution
Dr. Robert Sebra (a Co-Investigator in this study) is the Director of Technology Development at the Icahn Institute of Genomics and Multiscale Biology and the VP of Technology Development for Sema4 (a Mount Sinai spin-off company, dedicated to improving patients' wellness through aggregating, analyzing, and deriving personalized insights from health information and data). Sema4 is currently wholly owned by the Icahn School of Medicine at Mount Sinai. As VP of Technology Development for Sema4, Dr. Sebra receives financial compensation and has option grants in this privately held company.
Sema4 is involved in other research projects relating to schizophrenia, however, they have no involvement in the current study.
Molecular Profiling of Schizophrenia
Narrative In the United States, over a million people have schizophrenia with considerable morbidity, mortality, and personal and societal cost. We propose to use advanced and novel technologies to generate a broad range of genomic, epi-(Greek for `over', `above') genetic, and proteomic data collected from hundreds of postmortem brain samples from controls and from subjects who were diagnosed with schizophrenia. A particular strength of this proposal is that we will do much of this work in specific cell types that are often implicated in the disease. These data will provide a much needed resource to explore the genetic risk architecture and neurobiology of the disorder.
Filed on April 18, 2019.
Tell us what you know about Robert Sebra's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Robert Sebra”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Robert Sebra | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Sema4 | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.